Actively Recruiting
Studying Idiopathic Normal Pressure Hydrocephalus Biomarkers, Clinical Outcomes, and Disease Progression in Adults Aged 18 to 80
Led by Xuanwu Hospital, Beijing · Updated on 2024-05-24
200
Participants Needed
1
Research Sites
50 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying idiopathic normal pressure hydrocephalus iNPH and related disorders to understand their clinical characteristics and natural progression. This prospective single-center study aims to identify digital, imaging, and molecular biomarkers that can help with diagnosis and therapy development. It also explores the causes and molecular mechanisms of these conditions to better understand their effects and outcomes. Participants are divided into groups including those diagnosed with hydrocephalus and a normal group. The study involves advanced diagnostic tests such as high throughput sequencing, whole genome and exome sequencing, transcriptomics, proteomics, metabolomics, and imaging techniques like DTIALPS. These tests are conducted to gather comprehensive data on the disease and its biomarkers. During study visits, patients undergo standardized clinical examinations and complete clinical rating scales. Biosamples such as blood, urine, cerebrospinal fluid, and muscle biopsies may be collected optionally. Additional assessments like neurophysiological exams, patient-reported outcomes, and imaging are also performed. Researchers measure changes from baseline in DTIALPS imaging and various clinical scales six months after ventriculoperitoneal shunt surgery. The study includes monitoring cognitive function, gait, and molecular patterns, with participation lasting through these assessments and follow-ups.
CONDITIONS
Brief Title
Clinical Outcome in Patients With INPH
Research Team
F
fengzeng jian, md
X
xin qu, md
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here